Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus MORT copy number. DNA methylation of the MORT promoter in receptor negative and receptor positive tumors estrogen receptor (ER) (B), progesterone receptor (PR) (C), and human epidermal growth factor receptor 2 (HER2) (D). (E) DNA methylation of the MORT promoter in triple negative (TN) tumors, tumors positive for at least one receptor and a group of normal samples (p-value is for contrast TN vs. receptor (+) tumors). (F) DNA methylation of the MORT promoter in breast tumors classified into subtypes according to PAM50 (p-values are for contrast of individual tumor subtypes vs. normal). (G) DNA methylation of the MORT promoter in samples from patients >60 years of age compared to those from patients ≤60. (H) Association between amplification of the cyclin D1 locus and DNA methylation of the MORT promoter. (I) DNA methylation of the MORT promoter in samples with wild type TP53 compared to samples with mutated TP53. (J) DNA methylation of the MORT promoter in samples with wild type GATA3 compared to samples with mutated GATA3.

RPKM=reads per kilobase per million; CN=copy number; WT=wild type.